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Abstract
The C-terminal coiled-coil region of mouse and human cartilage matrix protein (CMP) self-
assembles into a parallel trimeric complex. Here, we report a general strategy for the development
of highly stable trimeric targeting ligands (tribody), against epidermal growth factor receptor
(EGFR) and prostate-membrane specific antigen (PSMA) as examples, by fusing a specific target-
binding moiety with a trimerization domain derived from CMP. The resulting fusion proteins can
efficiently self-assemble into a well-defined parallel homotrimer with high stability. Surface
plasmon resonance (SPR) analysis of the trimeric targeting ligands demonstrated significantly
enhanced target binding strength compared with the corresponding monomers. Cellular binding
studies confirmed that the trimeric targeting ligands have superior binding strength towards their
respective receptors. Significantly, EGFR-binding tribody was considerably accumulated in tumor
in xenograft mice bearing EGFR positive tumors, indicating its effective cancer targeting feature
under in vivo conditions. Our results demonstrate that CMP-based self-assembly of tribody can be
a general strategy for the facile and robust generation of trivalent targeting ligands for a wide
variety of in vitro and in vivo applications.
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Introduction
Targeting ligands play a pivotal role in all the in vitro and in vivo targeting applications.1
Depending on the nature of the application and the molecules to be targeted, some basic
properties of the target ligand, including molecular weight, surface charge, target-binding
specificity, affinity, and valency, should be optimized. It is now clear that one of the most
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critical parameters for satisfactory in vivo targeting is the valency of the targeting ligand.
Most monovalent targeting ligands, even those with very high binding affinities, have fast
dissociation rates and provide only modest retention time on the target antigen under
nonequilibrium physiological conditions.1 Impressively, nature addresses this problem by
extensively using multivalent interactions, as observed in almost all types of antibodies and
numerous multimeric interactive proteins. Currently, there is an unmet need for a technology
platform that allows for facile and robust development of desired panels of multivalent
targeting ligands that possess significantly increased target-binding strength, decreased
dissociation from target and thus longer and more accumulation on diseased tissues.
Monoclonal antibody is the major class of targeting ligands that has been widely used in
many biomedical fields.2 More than 20 monoclonal antibodies are being clinically used as
therapeutic agents and many more are under preclinical development.3 However,
immunoglobulin scaffold-based antibodies have intrinsic limitations, including large size
(~150 kDa), the presence of disulfide bonds, complex tetrameric structure and high cost of
production, that complicate their many applications.3 Substantial efforts have been made to
develop targeting ligands that can be quickly tuned to mimic antibodies with multivalent
features.2–5 The protein domains capable of forming multimeric complex have been
extensively investigated to generate recombinant proteins to achieve avidity effect through
multivalency.1,6 To develop a robust system that allows for facile generation of targeting
ligands with multivalent features, the multimerization domains should be of small sizes and
possess favorable biophysical properties, including thermal stability, resistance to protease,
and cost effectiveness in its production, while still able to generate highly stable multimeric
complex that can display multiple target-binding moieties in parallel. Different scaffolds that
allow for enhanced avidity have been reported.1,2,5–7 These scaffolds include the
bacteriophage T4 foldon domain, collagen like peptide (Gly-Pro-Pro)10, NC1 domain of
collagen XV and XVIII domain, and GCN leucine zipper domain for trimers,1,2,8,9,10
streptavidin and transcription factor p53 for tetramers,11 the B-subunit of bacterial verotoxin
and cartilage oligomeric matrix protein (COMP) for pentamers,12,13 and recently the
hyperthermophilic Sm protein for heptamers.6 However, most of these scaffolds are derived
from non-human proteins and have limited clinical application due to immunogenicity.
Ideally, the multimerization domain should be a highly conserved extracellular protein that
is abundant in mouse and human proteomes, which could result in less immunogenicity and
allow for smooth transition from animal studies to translational and clinical investigations.
While protein domains forming trimeric structures are widely used in nature, few possess
desired features that allow for effective development of trivalent ligands that are clinically
amenable. To address this unmet need, we chose the C-terminal domain from mouse CMP-1
(matrilin), which is highly homologous to human CMP-1, for the development of self-
assembly trivalent targeting ligands based on its remarkable property of forming stable
trimeric structures.14–16 As a major component of various cartilages, CMP-1, a 148 kDa
extracellular matrix glycoprotein serves as an adaptor in the assembly of the extracellular
matrix structure. The oligomerization characteristic of CMP or matrilin has been extensively
studied.14–16 There are four members of matrilins, namely, matrilin-1, -2, -3 and -4, whose
domain structures are highly conserved among species from chicken to human. It has been
reported that the matrilin-1 and -4 form trimeric, whereas matrilin-2 and -3 form tetrameric
complexes.16 The last 40 amino acids at the C-terminus of CMP-1 play an important role in
the formation of the trimeric structure.14,16 This C-terminal coiled-coil domain has a heptad
repeat on which hydrophobic residues reside in the first and the fourth positions, while polar
residues are common in the fifth and the last positions.14 The strong hydrophobic and ionic
interactions within this α-helical coiled-coil result in a parallel, disulfide-linked, and three-
stranded domain. The resulting rod-shaped trimeric structure, with a length of about 5.1 nm
and a diameter of 3 nm, has a high degree of co-operativity and high stability, with a Tm
higher than 60 °C at neutral pH, which can be attributed to the hydrophobic packing and a
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salt bridge between R27 and E32 residues.14 It appears that the trimeric structure was still
well maintained when the disulfide bonds that flank the N-terminus of the coiled-coil were
abolished.14
Overexpression of epidermal growth factor receptor (EGFR) and prostate-membrane
specific antigen (PSMA) receptor is frequently associated with various cancers including
lung, breast, prostate, and glioblastoma.3,17 Selective targeting towards EGFR or PSMA
holds the promise of early diagnosis and improved treatment.18,19 In this report, we describe
the use of the trimerization domain derived from the cartilage matrix protein that is abundant
and highly homologous in mouse and human to develop trivalent targeting molecules
(tribodies) with high stability and significantly enhanced avidity against EGFR and PSMA.
The resulting tribodies are extensively characterized and used for in vivo tumor targeting in
xenograft mouse models.
Materials and Methods
Plasmid Construction of Tribodies
Mouse cDNA library was used for the amplification of the gene encoding the mouse CMP-1
trimerization domain. Sequences coding EGFR-binding Z domain (Z1907) or PSMA
binding homing peptide were constructed as we reported previously.6 Each PCR fragment
was ligated into pET28b between NcoI and XhoI sites followed by sequencing to ensure that
each affinity molecule was generated correctly.
Expression and Purification of Tribodies
The plasmid containing a gene of interest was transformed into E. coli BL21 (DE3) Rosseta
cells and the positive clones were selected on LB plates containing kanamycin (50 μg/mL)
and chloramphenicol (34 μg/mL). A single colony was picked and grown in 5 mL of LB
overnight at 37 °C. The overnight grown cell culture was added to 500 mL of LB containing
kanamycin and chloramphenicol. The culture was grown at 37 °C till the OD600 reached
between 0.5 and 1.0, and 1 mM of IPTG was added to induce protein expression. After
induction at 22 °C for 16 h, the cells were spun down at 3000× g for 10 min at 4 °C, and the
pellet was stored at −20 °C prior to purification. To purify each monomeric and trimeric
molecules, each cell pellet was resuspended in buffer A (25 mM HEPES pH 7.4 and 50 mM
NaCl) and sonicated for 1 min for a total of 3 to 4 times. After cell lysis, the soluble fraction
was recovered by centrifugation at 12,000× g for 10 min at 4 °C. The resulting soluble
fraction was loaded into a TALON metal affinity column (Clontech, Mountainview, CA)
pre-equilibrated with buffer B (25 mM HEPES pH 7.4 and 300 mM NaCl). The column was
washed with 20 column volumes of buffer B, followed by extensive washing with buffer C
(buffer B and 20 mM imidazole). The targeting molecules were eluted with buffer D (buffer
B and 200 mM imidazole). The quality of purified proteins was examined by SDS-PAGE.
Native Gel Electrophoresis
An 8% discontinuous native gel was prepared in the absence of SDS and reducing agent
based on the standard Laemmli SDS-PAGE protocol. About 5 μg of highly purified
monomer or tribody was loaded for separation. Proteins were stained with Coomassie
brilliant blue R-250.
Circular Dichroism Spectroscopy
Highly purified monomeric and trimeric proteins were prepared in 10 mM phosphate buffer
(pH 7.5) and used for circular dichroism (CD) scanning with an AVIV model 202-01
Spectropolarimeter at the UNC Macromolecular interaction facility. To determine thermal
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stability, the CD spectra at 220 nm were measured from 25 °C to 94 °C, and the ramp was
cool down to 25 °C followed by measuring the CD spectra at 220 nm again from 25 °C to 94
°C. The melting temperature (Tm) was calculated as a temperature which has the midpoint
CD spectra between the lowest and the highest CD spectra with reversible melting curve.
Protease Resistance
Thermolysin, papain, and MMP-9 were used for the protease resistance assays. Thermolysin
and papain were purchased from Sigma-Aldrich, MO. MMP-9 was purchased from EMD
Millipore (Billerica, MA). Approximately 2 μg of monomeric or trimeric targeting ligands
were incubated with thermolysin (10 ng of thermolysin per μg of protein). The protease
digestion was performed in an HBS buffer (10 mM HEPES, pH 7.4 and 150 mM NaCl) for
30 min at 37 °C. The reaction mixtures were applied to SDS-PAGE to examine protein
degradation. Approximately 2 μg of monomeric or trimeric targeting ligands were incubated
with 20 ng of papain for 30 min at 37 °C. The reaction was performed in a papain digestion
buffer (50 mM phosphate buffer pH 7.0, 0.5 mM EDTA). Papain was activated by 5 mM of
L-cysteine, followed by removing L-cysteine using a MWCO 5 kDa spin column through
centrifugation. The reaction mixtures were applied to SDS-PAGE to examine protein
degradation. Approximately 2 μg of monomeric or trimeric targeting ligands were incubated
with 100 ng of MMP-9 for 4 h at 37 °C. The reaction was performed in a MMP-9 digestion
buffer (50 mM Hepes pH 7.5, 10 mM CaCl2, 0.02% BRIJ-35). The reaction mixtures were
applied to SDS-PAGE to examine protein degradation.
Target-binding Analysis Using Biacore
BIAcore 2000 (BIAcore AB, Uppsala, Sweden) was used for surface plasmon resonance
analysis. The extracellular domain of recombinant human EGFR or PSMA (R&D Systems,
Minneapolis, MN) was diluted in 10 mM sodium acetate pH 5.0 and immobilized on CM5
sensor chip (GE healthcare, Piscataway, NJ) to achieve ~2,500 resonance units by amine
coupling according to the manufacturer’s instruction. Various concentrations of monomeric
and trimeric ligands were injected into the flow cell in a HBS-P buffer (10 mM HEPES, pH
7.4, 150 mM NaCl, and 0.005% surfactant P20) at a flow rate of 20 μl/min. The association
and dissociation constants were calculated using BIA evaluation software by fitting data on
one-toone Langmuir binding model.
Cell Culture
All cell lines including EGFR positive A431, EGFR negative Jurkat, PSMA positive LNCaP
and PSMA negative PC3 cancer cells were obtained from the Tissue Culture Facility at
UNC-Chapel Hill. All cell lines were maintained by serial passage in the appropriate media
containing 10% fetal bovine serum in a 5% CO2 incubator at 37 °C.
Confocal Microscopy
Each cell type (about 2×104) was seeded onto coverslips and allowed to grow in an
appropriate media for 16 h. The resulting coverslips were washed twice with 1× PBS,
followed by incubation with different concentrations of FITC-labeled monomeric and
trimeric ligands for 30 min at room temperature. After incubation, the coverslips were
washed three times with 1× PBS. The resulting samples were examined with a Zeiss LSM
510 confocal microscope at the UNC microscopy core facility.
Flow Cytometry
Cell binding of the monomeric and trimeric ligands was evaluated by using flow cytometry.
Approximately 2×104 cells were grown on a 24-well plate for 16 h. After washing with 1×
PBS, the cells were incubated with an appropriate amount of FITC-labeled monomeric or
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trimeric ligand for 30 min at room temperature, followed by washing twice with 1× PBS.
The resulting samples were analyzed by flow cytometer (BD FACS Canto flow cytometry)
and the data analyzed by the Flow Jo System (Tree star, Inc. Ashland, OR). FITC-labeled
anti-PSMA antibody (MBL, Nagoya, Japan) was used as a positive control.
Serum Stability
Purified tribody (5 μg) was incubated at 37 °C with 100 μL of mouse serum (50 mg/mL,
Sigma-Aldrich, MO) for 6 and 24 h, respectively. After incubation, 10 volumes of buffer A
were added and the protein was recovered by using Co2+-NTA column as described above.
Cell Proliferation MTS Assay
The CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit from Promega
(Madision, WI) was used for the MTS cell proliferation assays. Approximately 1× 104 cells
were seeded in each well of a 96-well plate and grown for 16 h at 37 °C. Appropriate
amount of each targeting ligand was added and incubated with the cells for 36 h. 10 μM Cis-
platinum (II) diamine dichloride (Sigma-Aldrich, St Louis, MO) was used as a positive
control. After incubation, approximately 20 μl of MTS/PMS solution was added to each well
followed by incubation for 4 h at 37 °C. The absorbance at 490 nm was recorded using an
ELISA plate reader.
PEGylation and Fluorescent Labeling with Alexa 750
Highly purified monomeric or trimeric ligand was incubated with 30 kDa mPEG-NHS ester
(Creative PEGWorks, Winston Salem, NC) in 1× PBS (1:15 molar ratio) at room
temperature for 4 h. The reaction mixture was purified by Co2+-NTA column
chromatography to remove unreacted PEG. After PEGylation, Alexa 750 succinimidyl ester
(Life technology, Grand Island, NY) was added (10:1 molar ratio) and incubation for 2 h at
room temperature. Un-reacted Alexa 750 was removed through extensive dialysis against 1×
PBS using a dialysis membrane with 5 kDa MWCO.
Animal Study
Female athymic nude mice of 6–8 weeks were purchased from Charles River Laboratories
(Wilmington, MA). All work performed on animals were in accordance with and approved
by UNC Institutional Animal Care and Use Committee. Specifically, A431 cells (5× 106)
were subcutaneously injected onto the lower back of female nude mice (about 20 g), and
were allowed to grow to tumor size of about 200 mm3. Approximately 0.5 nmol of
PEGylated, Alexa750-labeled ZEGFR monomer or trimer in DPBS was applied to the mice
by intravenous injection. Six hours post-injection, mice were sacrificed followed by organ
isolation through cervical dislocation. The images of tumor and each organ were taken by
the Kodak In-Vivo Imaging System FX-PRO (Carestream Health, Inc). Densitometric
analysis of tumor signal was performed by Image J (NIH, Bethesda, MD).
Results
Design and Generation of Tribodies
In order to generate trimeric targeting ligands, we started with the 43-residue trimerization
domain from mouse CMP-1:
EEDPCACESILKFEAKVEGLLQALTRKLEAVSGRLAVLENRII. This sequence is highly
homologous to the same trimerization domain of human CMP-1:
EEDPCACESLVKFQAKVEGLLQALTRKLEAVSKRLAILENTVV, making it easy to
switch to the human version if translational application is desired. In principle, many target-
binding moieties can be fused with this trimerization domain for the facile generation and
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conversion into the trimeric form. These targeting moieties include VH or VL domains from
the natural antibodies, non-immunoglobulin protein domains that mimic natural antibodies,
and various short homing peptides isolated from phage display or other selection strategies.1
To demonstrate that this tribody approach can be generally applied to fuse with targeting
moieties with different 3D structures from non-structural homing peptides to well-folded
protein domains, and with target-binding affinities from low to high, we chose a PSMA-
binding short homing peptide HPPSMA (WQPDTAHHWATL) as an example for a low
affinity target-binder,17 and an EGFR-binding Z domain as an example for a high affinity
target-binder (Figure 1A).4 To compare the tribody with its monomeric form, the
monomeric ZEGFR targeting molecule was constructed without the trimerization domain. We
also truncated the trimerization domain by deleting the last 14 residues that are critical for
intermolecular interaction and mutating Cys to Ala to disrupt the disulfide bond (Table 1).
The resulting domain is not possible to trimerize, and was used for the generation of
monomeric PSMA binding protein. The coding sequence for each recombinant fusion
protein was synthesized and cloned into expression vector pET-28b for over-expression in
E. coli (Table 1). A C-terminal His-tag was introduced to facilitate affinity purification. The
expression of each tribody and its corresponding monomer was induced by the addition of 1
mM IPTG. One of the key advantages of using the trimerization domain of CMP-1 is that its
self-assembly considerably favors a trimeric form compared to other trimeric and
pentameric scaffolds.20,21 The CMP based recombinant proteins were highly expressed and
purified to nearly homogeneity through Co2+-NTA purification. Indeed, more than 99% of
the molecules exist in the trimeric form following purification with only a trace amount of
monomer and dimer (Figure 1B). In order to verify the prominence of the trimer, native gel
electrophoresis was performed. As shown in Figure 1C, both EGFR targeting and PSMA
targeting tribodies existed only as a trimer under native and non-denaturing conditions.
These results indicated that the tribodies are self-assembled highly efficiently, and can be
purified as homogeneous trimeric complexes by a one-step Co2+-NTA chromatography
procedure.
Thermal Stability and Protease Resistance of Tribodies
In order to use the tribodies under in vivo conditions, the biophysical properties such as
solubility, thermal stability and resistance against protease degradation should be
investigated. The CMP-based tribodies were highly expressed in E. coli as soluble
recombinant proteins. To determine the thermal stability of the tribodies, we first performed
Circular Dichroism (CD) analysis using highly purified monomeric and trimeric molecules
by gradually increasing temperature from 25 °C to 94 °C to examine the secondary structure
changes (Figures 2A to 2F). It was found that the melting temperature (Tm) of the
monomeric HPPSMA was about 65 ± 1 °C (Figure 2B). The HPPSMA trimer showed
remarkable stability when temperature was increased from 25 °C to 94 °C with a reversible
melting curve (Figure 2B). Significantly, trimeric HPPSMA appears to be more stable than
the monomeric HPPSMA at higher temperatures (Figure 2C). Since both the targeting moiety
and the flexible linker in trimeric HPPSMA are short peptides that are presumably non-
structural, the observed remarkable thermal stability of HPPSMA tribody can be attributed to
the highly stable trimerization domain. The Tm of the ZEGFR monomer was approximately
60 ± 2 °C (Figure 2E). The ZEGFR trimer also showed high stability when temperature was
increased from 25 °C to 94 °C (Figure 2E). Although the melting curve of the ZEGFR trimer
was reversible only in the range from 25 °C to 60 °C (Figure 2F), the second and third
melting curves showed similar patten as their corresponding monomer (Figure 2E),
suggesting a Tm around 61 ± 1 °C for the ZEGFR trimer. Since ZEGFR tribody was very
stable when temperature was increased to 60 °C, it is likely that Tm of ZEGFR tribody is
much higher than 61 °C and that the first heating to 94 °C causes irreversible changes that
result in reduction of the Tm of subsequent measurements. It appears that another transition
Kim et al. Page 6













above 80 °C in ZEGFR monomer and trimer melting curves was evident. While the results
were reproducible, the nature of this transition is not clear.
Protein degradation by serum proteases is another obstacle that limits in vivo applications of
many targeting ligands. To investigate this issue, we performed protease-mediated digestion
of the targeting ligands by using thermostable metallopeptidase thermolysin, cysteine
protease papain, and matrix metallopeptidase-9 (MMP-9). Significantly, all the monomeric
and trimeric molecules were resistant to thermolysin digestion (Figure 3). Figure 4A shows
that both the monomeric and trimeric molecules were resistant to papain. MMP-9 is one of
the best characterized extracellular proteases that are overexpressed in numerous tumors.
Figure 4B shows that both the monomeric and trimeric molecules were resistant to MMP-9
digestion (Figure 4B), whereas the control protein that contains a MMP-9 cleavage site was
readily cleaved. These results suggest that these tribodies can be used under in vivo
conditions when biologically active proteases are highly abundant.
In Vitro Target-binding Towards Immobilized and Cell Surface Targets
To examine whether these tribodies have desired targeting feature, we first used surface
plasmon resonance (SPR) to compare the target-binding properties of the monomeric and
the corresponding trimeric targeting ligands. Each purified protein target (the extracellular
domain of EGFR or PSMA) was immobilized on CM5 sensor chip through amine coupling.
Various concentrations of monomeric or trimeric targeting ligands were injected into the
flow cell for binding strength analysis. To examine the multivalent effect, relatively low
concentrations of tribodies were used in the flow phase. As shown in Figure 5 and Table 2,
the monomeric ZEGFR rapidly dissociated from EGFR immobilized on chip surface (kd
~6.78×10−4 1/s) with a binding affinity around 2.06 ± 0.51 nM. Significantly, the ZEGFR
tribody dissociated very slowly compared to the monomer. The multiple target-binding sites
involved in the interaction between tribody and EGFR significantly increase the local
concentration of the affinity unit, thus effectively providing a decreased overall off-rate.
This multivalent avidity or functional affinity is distinct from the intrinsic affinity used to
describe the single antibody-antigen interaction, and can be orders of magnitude higher than
the conventional affinity of a monovalent interaction. As shown in Figure 5B, the
dissociation rate of the tribody observed from the SPR experiments was indeed significantly
decreased. However, it is difficult to fit the data on any BIAevaluation model for multivalent
kinetic analysis, presumably due to the complexity of the multivalent interaction between
tribody and dimeric EGFR receptor. Therefore, the kinetic parameters of this EGFR-binding
tribody are not calculated. In the case of PSMA tribody, we found that PSMA immobilized
on CM5 sensor chip was not functional when examined with widely used anti-PSMA
antibody, making it impossible to measure the PSMA-binding of HPPSMA tribody. To
address this issue, flow cytometry was adopted to estimate the binding of FITC-labeled
HPPSMA monomer and tribody with native PSMA present on the surface of cancer cells
(Figure 6), while FITC-labeled anti-PSMA antibody was used as a positive control. As
shown in Figure 6A, anti-PSMA antibody bound to LNCaP cells but not PC3 cells when
used at 100 nM. HPPSMA monomer showed no obvious binding with both PSMA positive
LNCaP cells and PSMA negative PC3 cells (Figure 6B). However, as shown in Figure 6B,
HPPSMA tribody showed selective binding toward LNCaP but not PC3 cells, with a Kd of
455 ± 24 nM.
We further confirmed the significantly enhanced target-binding of the tribodies by using
biomarker-expressing cell lines. A431 cells have a high expression level of EGFR and were
used as positive cells, while Jurkat cells were used as negative cells. As shown in Figure 7A,
the trimeric targeting ligands demonstrated much stronger cell-binding compared to the
monomeric forms. In the negative control experiments, both FITC-labeled ZEGFR monomer
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and trimer failed to bind to Jurkat cells even at high concentration (100 nM). In contrast,
ZEGFR tribody can recognize A431 cells with a concentration as low as 1 nM, whereas more
than 10 fold higher concentration of ZEGFR monomer was required to observe similar cell-
binding extent. In the case of HPPSMA, a FITC-labeled HPPSMA tribody can bind to PSMA
positive LNCaP cells with a concentration as low as 100 nM (Figure 7B). We found that the
monomeric PSMA homing peptide did not result in specific cell-binding signal even used at
high μM concentrations (Figure 7B and unpublished data). Since the target-binding affinity
of monomeric HPPSMA was too weak to measure, we were not able to determine the exact
fold of increase in target-binding strength for HPPSMA. Nevertheless, the results clearly
indicate that the CMP-based trimerization approach allows for a quick conversion of a short
homing peptide with undetectable binding affinity to a trivalent form with target-binding
strength close to many monoclonal antibodies. Taken together, both ZEGFR and HPPSMA
tribodies recognize their target receptors with greatly enhanced binding strength without
sacrificing specificity compared with their corresponding monomers.
Serum Stability and Toxicity
Successful in vivo application of tribodies including imaging or therapy requires excellent
serum stability and non-toxicity. To address the stability of the tribody in serum, trimeric
ZEGFR was incubated with mouse serum at 37 °C for up to 24 h. After incubation, the
protein was recovered by Co2+-NTA chromatography. As shown in Figure 8A, ZEGFR
tribody displayed unusually high stability in mouse serum without detectable degradation
even after 24 h at 37 °C. The toxicity of the ZEGFR tribody was also examined by using the
cell proliferation assay. As illustrated in Figure 8B, no cell growth inhibition was observed
when the ZEGFR tribody was used at 500 nM, a concentration that results in very strong cell-
binding signals. Taken together, these results demonstrated that ZEGFR tribody showed high
serum stability and non-toxicity, and held the great potential for various in vivo and
translational applications.
In Vivo Tumor Targeting
To examine the in vivo application of the trimeric targeting ligands, we used the EGFR-
binding tribody to target tumor in xenograft mouse models. The molecular weight of the
tribody is in the range of 30 kDa (for HPPSMA) to 58 kDa (for ZEGFR). To increase the
circulation time, both the monomeric and trimeric ZEGFR were PEGylated using 30 kDa
PEG-NHS ester. To examine whether ZEGFR tribody can efficiently target tumor on which
EGFR was highly expressed, Alexa 750-labeled, PEGylated ZEGFR monomer and tribody
were intravenously injected into A431 xenograft nude mice. Six hours after injection, mice
were sacrificed and the organs were isolated. The images of each organ and tumor were
taken by an In-Vivo Imaging System FX-PRO. As shown in Figure 9, when the PEGylated
tribody was used, the strongest accumulation was found in tumor with no or minimal
accumulation in the heart, lungs, spleen, and liver. There was modest accumulation in the
kidney, presumably due to the well-known renal elimination of the animal. Approximately
54% of the fluorescent signal from ZEGFR tribody was accumulated in the tumor, compared
to that of 7.7% from the monomer. These results clearly indicate that the tribody holds great
promise for in vivo tumor targeting applications.
Discussion
In this study, we report the successful development and application of a novel class of
trimeric targeting ligands based on the highly conserved trimerization domain of mammalian
CMP-1. Compared with other trimeric scaffolds that have been reported, 8–10,21–22 this
tribody approach possesses several key advantages. First, this trimerization domain is
derived from a highly conserved extracellular protein that is abundant in both mouse and
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human. Presumably, the tribodies that are used for animal studies and translational
applications can be readily generated with similar targeting features and low
immunogenicity. This will greatly facilitate smooth transition from in vitro investigation to
in vivo application. Second, the tribody has remarkable biophysical features with regard to
thermal stability and protease resistance (Figures 2, 3 and 4). They were very stable when
the temperature was up to 90 °C (Figure 2). Also, the tribodies were resistant to the
degradation mediated by different proteases, including physiologically relevant papain and
MMP-9 (Figures 3 and 4). While these tribodies existed as a trimer predominantly under
denaturation condition such as boiling and in the presence of SDS (Figure 2), the
bacteriophage T4 foldon derived trimer dissociated into a monomeric form after boiling.8
The human collagen XVIII NC1 domain, another trimerization domain that has been used
for the generation of multimeric antibody, was sensitive to heat-induced denaturation and
protease degradation.9 Third, the trimerization of tribody is a convenient and highly efficient
self-assembling process (Figure 1). Compared to most other multimerization domains such
as mucin 1-based trimer and COMP-based pentamer in which intermolecular disulfide bond
linkages are indispensable for the formation of multimeric complexes,20,21 it was found that
the tribody efficiently self-assembled into a stable trimeric form in the absence of any
disulfide bonds, presumably due to the strong and extensive intermolecular hydrophobic and
ionic interactions among the trimeric complex. This feature makes the tribody very useful in
many in vitro and in vivo applications under reducing conditions. The trimer predominance
of this system also provides an advantage on cost effectiveness over other disulfide bond-
mediated trimers and pentamers, which are often generated with a significant amount of
intermediate forms that are extremely difficult and time-consuming to purify.13,23,24 For
example, the GCN4 isoleucine zipper based-trimer as well as the chicken tenascin C-
mediated trimer often co-exist with the corresponding monomer and dimer,23,24 making it
critical to remove the intermediate forms through often inefficient gel filtration
chromatography. Fourth, the self-assembly multimerization process results in significant
increase in molecular weights for short homing peptides and small target-binding domains,
which otherwise display much shorter half-life in vivo due to rapid proteolytic cleavage and
renal clearance.
The enhancement of the binding strength of a tribody against a cell surface receptor was
demonstrated by SPR experiments (Figure 5), supporting the avidity effect of the tribody
and further making it an attractive reagent for in vivo tumor detection and targeting. Cellular
binding analysis using biomarker-expressing cell lines demonstrated that the tribodies
recognized their corresponding receptors much more tightly than the monomer counterparts
(Figure 7). It is worth mentioning that the length of the flexible linker could be critical to
achieve desired multivalency and should be tuned depending on the nature of the targeting
moiety and the receptor. The experimental conditions for SPR are artificial. The density of
the receptor used in SPR is different from the native biomarker on the cell surface. It should
be noted that unlike the surface of cancer cells where a biomarker of interest is present with
thousands of other receptors and membrane-bound proteins, only purified biomarker was
present on the surface of SPR biosensor. It is expected that this absence of competition
during in vitro assays facilitates binding of tribody through multivalent interaction with
more than one receptor. While the results from such in vitro analysis do not necessarily
correlate well with what observed by using living cells, they reveal more precisely the
biochemical and biophysical interactions (i.e., kon and koff) between a trimeric targeting
ligand and a purified receptor of interest, which facilitate the rational design of targeting
ligands with desired features.
Tribodies showed remarkable stability against protease degradation and serum proteases
(Figures 3,4 and 8A). Also, they did not show detectable cell toxicity when applied up to
500 nM (Figure 8B), suggesting that they have the potential of being utilized for in vivo
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tumor targeting. Compared to full-length monoclonal antibodies and small protein domain-
based antibody mimics, the modest size and slower off-rate of tribody (i.e. 58 kDa for
ZEGFR tribody) could presumably provide rapid tissue penetration and longer retention time
on a target receptor on diseased tissues.9,19 To demonstrate the in vivo application of the
tribody, we performed in vivo tumor targeting using PEGylated tribody in mice bearing
EGFR-positive tumor. It is well known that PEGylation of a targeting ligand aids in the
reduction of nonspecific binding and increase of circulatory half-life.25 Indeed, effective
targeting to the EGFR-positive A431 tumor was demonstrated 6 h post-injection (Figure 9).
The tribody was accumulated most in the tumor, with no or minimal accumulation in the
heart, lungs, spleen, and liver. It was not surprising that modest accumulation was found in
kidney, due to its well-known function in clearance of macromolecules. It has been reported
that ZEGFR monomer also bound murine EGFR.26 This probably explained why there was
some accumulation in mouse liver, which is known to have relatively more expression of
EGFR compared to other organs.
Despite the advantages we have demonstrated in this work, the CMP-based tribody system
does have its limitations. First, it is unrealistic to fuse with a very large protein domain,
particular those with complex structures or multiple cysteine residues, while still expect to
achieve the dramatic multivalent effect as we demonstrated for short homing peptides and
target-binding small protein domains. Presumably, the close proximity of the three large
domains in the tribody will greatly complicate the intermolecular interaction and disulfide
bond exchange, resulting in incorrect disulfide bond formation and misfolding of the
protein, despite the use of a long flexible linker. This will greatly reduce the multivalent
effects, barely less than 10-fold increase as recently reported by Saha and co-workers,27
even under in vitro conditions such as in SPR experiments. Second, one critical question to
ask is which valency is enough and better to achieve the desired avidity effect? We have
reported previously the pentameric and heptameric targeting ligands by using distinctive
self-assembly approaches.6,19 Based on the in vitro biochemical and biophysical
characterization that can be quantified, it appears that the trimeric targeting ligands perform
as well as, and sometimes even better than, the pentameric and heptameric targeting
ligands.6,19 However, caution should be taken to draw a general conclusion, because the
interaction between a multivalent ligand with a cell surface receptor is highly dependent on
the molecular nature, oligomeric status, surface density, correct conformation, post-
translational modification, and other biochemical and biophysical properties of the receptor.
Our studies shed light on the further development of multivalent targeting ligands against
numerous cell surface receptors that are implicated in different human diseases.
In summary, we have developed trimeric targeting ligands based on the highly conserved
CMP trimerization domain in mouse and human with remarkable stability against heat and
proteolysis as well as significantly improved target binding affinity and effective in vivo
tumor targeting feature in animals. Facile and tunable production of tribody suggests its
great potential in specific tumor imaging and targeted delivery of numerous therapeutic
agents.
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Figure 1. Schematic diagram and the purication of the tribody
A) a self-assembled trimeric targeting ligand consists of a target binding domain (ZEGFR) or
homing peptide (HPPSMA), a flexible hinge linker, and a trimerization domain derived from
the C-terminus of mouse CMP-1. His×6 tag was engineered at the C-terminus of each ligand
to facilitate affinity purification. B) Purification of the monomeric and trimeric targeting
ligands on SDS-PAGE. ZEGFR monomer, ZEGFR trimer, HPPSMA monomer, and HPPSMA
trimer were purified by metal affinity column chromatography and loaded on 12% SDS-
PAGE for analysis. NR stands for nonreducing condition, and R stands for reducing
condition with 10 mM DTT. C) Native gel electrophoresis. Purified monomeric and trimeric
proteins (5 μg) were loading on an 8% native gel to analyze the oligomeric status. Proteins
were stained by Coomassie brilliant blue.
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Figure 2. Analysis of heat induced denaturation using Circular Dichroism
A) CD spectra of HPPSMA monomer and HPPSMA trimer were recorded from 190 nm to 260
nm at 25 °C, respectively. B) CD spectra were recorded at various temperatures from 25 °C
to 94 °C. The ellipticity at 220 nm was used for analysis. C) CD spectra of HPPSMA
monomer and HPPSMA trimer was recorded from 190 nm to 260 nm at 25 °C and 94 °C,
respectively. D) CD spectra of ZEGFR monomer and ZEGFR trimer were recorded from 190
nm to 260 nm at 25 °C, respectively. E) CD spectra of ZEGFR monomer and ZEGFR trimer
were recorded at various temperatures from 25 °C to 94 °C. The ellipticity at 220 nm was
used for analysis. F) CD spectra of ZEGFR trimer were recorded at various temperatures
from 25 °C to 60 °C. The ellipticity at 220 nm was used for analysis.
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Figure 3. Analysis of protease resistance using thermolysin
Each purified protein (A: ZEGFR monomer and trimer, B: HPPSMA monomer and trimer)
was incubated with thermolysin at 37 °C for 30 min. The reaction mixture were loaded on a
12 % SDS-PAGE for analysis.
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Figure 4. Protease resistance assay using papain and MMP-9
A) Each purified protein (ZEGFR monomer and trimer, HPPSMA monomer and trimer) was
incubated with papain at 37 °C for 30 min with BSA as a positive control. The reaction
mixtures were loaded on 12 % SDS-PAGE. B) MMP-9 was incubated with each purified
protein (ZEGFR monomer and trimer, HPPSMA monomer and trimer) as well as an
engineered protein which contains MMP-9 clevage site (PLGLAG). The reactions were
performed at 37 °C for 2 h. The reaction mixtures were loaded on 12 % SDS-PAGE.
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Figure 5. Biacore analysis of target binding properties
Recombinant human EGFR-Fc was immobilized on a CM5 biosensor chip via amine
coupling. Different concentrations of targeting ligands (A. ZEGFR monomer, and B. ZEGFR
trimer) were injected onto the biosensor channels and the analysis was performed at a flow
rate at 20 μl/min at room temperature.
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Figure 6. Flow cytometry for cell-binding
A) PSMA positive LNCaP cells and PSMA negative PC3 cells were grown on a 6-well plate
for overnight. 100 nM of FITC labeled anti-PSMA was incubated with LNCaP or PC3 cells
at 25 °C for 30 min. The cell-binding signals were analyzed by flow cytometry. MFI: mean
fluorescent intensity. B) PSMA positive LNCaP cells and PSMA negative PC3 cells were
grown on a 24-well plate for overnight. FITC-labeled HPPSMA monomer and HPPSMA
trimer at various concentrations were incubated with LNCaP or PC3 cells at 25 °C for 30
min. The cell-binding signals were analyzed by flow cytometry. MFI: mean fluorescent
intensity.
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Figure 7. Comparison of the binding of monomeric and trimeric targeting ligands with targets
on cell surface
A) EGFR positive A431 cells and EGFR negative Jurkat cells were grown on coverslides.
Different concentrations of FITC-labeled ZEGFR monomer and ZEGFR trimer were incubated
with cells for 30 min at 25 °C. B) PSMA positive LNCaP cells and PSMA negative PC3
cells were grown on coverslides. Different concentrations of FITC-labeled HPPSMA
monomer and HPPSMA trimer were incubated with cells for 30 min at 25 °C. The cell-
binding signals were visualized by confocal microscopy. The scale bars indicate 20 μm.
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Figure 8. Serum stability and toxicity
A) Serum stability: purified ZEGFR tribody (5 μg) was incubated with mouse serum (5 mg)
for 0, 6, and 24 h, respectively. After incubation, the proteins in the reaction mixture were
recovered with Co2+-NTA resin. The recovered tribodies were loaded on a 12% SDS-PAGE
to examine stability. Lane 1: 0 h; lane 2: 6 h; lane 3: 24 h. B) Toxicity: A431 cells were
incubated with various concentrations of ZEGFR tribody for 36 h at 37 °C. Cisplatin (10 μM)
was used as a positive control. Cell proliferation was determined by using absorbance at 490
nm (A490). Three repeated assays were performed.
Kim et al. Page 26













Figure 9. In vivo tumor targeting using PEGylated monomeric and trimeric ZEGFR
PBS (1), 0.5 nmol of PEGylated, Alexa750-labeled monomeric ZEGFR (2), and 0.5 nmol of
PEGylated, Alexa750-labeled trimeric ZEGFR (3) in PBS were injected to A-431 xenograft
nude mice. 6 h after injection, mice were sacrificed and the images of tumor and each tissue
were taken by Kodak In-Vivo Imaging System FX-PRO.
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Table 1
Amino acid sequences of tribody component
Amino acids
ZEGFR MVDNKFNKEM WAAWEEIRNL PNLNGWQMTA FIASLVDDPS QSANLLAEAK KLNDAQAPK
TPPSMA WQPDTAHHWATL
Hinge Linker GPQPQPKPQPK PEPEPQPQGG
Trimerization domain EEDPCACESILKFE AKVEGLLQALTRK LEAVSGRLAVLENRII
Truncated Trimerization domain EEDPAAAESILKFE AKVEGLLQALTRKLE
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Table 2
Binding constants of ZEGFR monomer
The association and dissociation constants were calculated using BIA evaluation software by fitting data on
one to one Langmuir binding model.
ka(1/Ms) kd(1/s) KD(M)
ZEGFR Monomer 3.29 ± 0.82 × 105 6.78 ± 1.69 × 10−4 2.06 ± 0.51 × 10−9
Biochemistry. Author manuscript; available in PMC 2014 October 15.
